Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL)

Annals of Hematology
Luigi RigacciEmilio Iannitto

Abstract

Bendamustine is an alkylating agent with a nitrogen mustard group and a purine-like benzimidazole group. The aim of this study was to collect all the Italian experiences with this drug in order to evaluate the results in term of response to therapy and toxicities. We analyzed lymphoma patients treated in 24 Italian haematological centres with bendamustine alone or in combination with anti-CD20 antibody. One hundred seventy-five relapsed or refractory lymphoma patients were enrolled. The median age was 69 years (range 26-87). Seventy-nine patients were relapsed, 35 were refractory and 61 presented a progressive disease after partial response. The diagnoses were 60 indolent non-follicular lymphomas, 34 diffuse large B-cell lymphomas, 48 follicular lymphomas, 30 mantle cell lymphomas and three peripheral T-cell lymphomas. All patients were evaluable for response: 52 (29%) with complete remission, 72 (43%) with partial response with an overall response rate of 71%, and 51 non-responders. With a median observation period of 10 months (1-43), 70% of patients are alive. In summary, this retrospective study shows that treatment with bendamustine alone or in combination with rituximab is a safe and effective regimen in a subset of multi...Continue Reading

References

Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Mar 4, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·N L HarrisC D Bloomfield
Aug 15, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P SchöffskiA Ganser
Feb 24, 2001·Journal of Cancer Research and Clinical Oncology·R KathK Höffken
May 23, 2001·Drugs·J A Balfour, K L Goa
Feb 19, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P Boyle, J Ferlay
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mathias J RummelParis S Mitrou
Jan 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lorenzo M LeoniChristina C Niemeyer
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonathan W FriedbergBruce D Cheson
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Jul 16, 2010·Cancer Science·Ken OhmachiUNKNOWN Japanese Bendamustine Lymphoma Study Group
Nov 19, 2010·Expert Review of Hematology·Marco MontilloEnrica Morra

❮ Previous
Next ❯

Citations

Aug 24, 2012·Cancer Cell International·Jiangning ZhaoQuanyi Lu
Jan 1, 2014·Annals of Hematology·Qingqing CaiMichael Wang
Nov 5, 2013·Leukemia & Lymphoma·Enrico DerenziniBruce D Cheson
Sep 14, 2012·Expert Opinion on Drug Metabolism & Toxicology·Anna Korycka-Wołowiec, Tadeusz Robak
Feb 27, 2015·Expert Opinion on Drug Safety·Eileen Mary Boyle, Franck Morschhauser
Jan 31, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V A MorrisonS M Lichtman
Feb 12, 2015·Clinical Pharmacology and Therapeutics·L AlinariK A Blum
Jul 30, 2016·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Dominick LamonicaMyron S Czuczman
Jun 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V A MorrisonS M Lichtman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.